Form 8-K - Current report:
SEC Accession No. 0001420720-25-000010
Filing Date
2025-02-10
Accepted
2025-02-10 16:06:01
Documents
16
Period of Report
2025-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20250210x8k.htm   iXBRL 8-K 33261
2 EX-99.1 ibio-20250210xex99d1.htm EX-99.1 20683
3 GRAPHIC ibio-20250210xex99d1002.jpg GRAPHIC 3180
  Complete submission text file 0001420720-25-000010.txt   187075

Data Files

Seq Description Document Type Size
4 EX-101.SCH ibio-20250210.xsd EX-101.SCH 4267
5 EX-101.DEF ibio-20250210_def.xml EX-101.DEF 3990
6 EX-101.LAB ibio-20250210_lab.xml EX-101.LAB 13975
7 EX-101.PRE ibio-20250210_pre.xml EX-101.PRE 10318
18 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20250210x8k_htm.xml XML 4641
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 25605775
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)